Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1992-09-21
1999-03-30
Wolski, Susan
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 13, 436518, 436523, 436528, 436531, 436534, 53038825, G01N 33573, G01N 33546, C07K 1636
Patent
active
058887490
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 of PCT/JP91/01736, filed Dec. 19, 1991.
TECHNICAL FIELD
The present invention relates to a group of various types of monoclonal antibodies having reactivity with a human plasmin-.alpha..sub.2 -plasmin inhibitor complex (hereinafter optionally referred to as "PIC"), various types of hybridomas secreting the above monoclonal antibodies, and a method for immunologically determining a human plasmin-.alpha..sub.2 -plasmin inhibitor complex using the above monoclonal antibodies.
BACKGROUND ART
In the plasma of patients suffering from disseminated intravascular coagulation (DIC) and in the plasma of patients being treated by the thrombolytic therapy using urokinase or tissue plasminogen activators (t-PA), a plasminogen is activated to produce a plasmin. The resulting plasmin immediately forms a complex with an .alpha..sub.2 -plasmin inhibitor (.alpha..sub.2 PI: Aoki et al., J. Biol. Chem., 251, 5956-5965, 1976) at a ratio of 1:1 in circulating blood. The complex is the above PIC. Therefore, by measuring the PIC, it is possible to detect the activation of the plasmin. Recently, the PIC in the plasma is considered important in the diagnosis of DIC, as a molecular marker for monitoring the thrombolytic therapy, and so on. Accordingly, it is necessary to accurately and simply measure the amount of PIC in the blood or plasma.
As conventionally known methods for measuring PIC, there may be mentioned the following five methods. The first method uses two-dimensional crossed immunoelectrophoresis. The second method is a latex agglutination using polyclonal antibodies which recognize the necantigen of PIC. The third method is an enzyme immunoassay wherein a polyclonal antibody against the plasminogen and a polyclonal antibody against the .alpha..sub.2 -plasmin inhibitor, and one of them is immobilized and the other is labelled by an enzyme. The fourth method is an enzyme immunoassay wherein a monoclonal antibody which specifically recognizes the sites inhibiting the fibrinolysis action of the plasmin and existing in the .alpha..sub.2 -plasmin inhibitor, and a polyclonal antibody against a plasmin are used; one of them is immobilized and the other is labelled by an enzyme; and the plasma specimen is diluted 1200-fold for measurement. The fifth method is the latex agglutination wherein two or three types of monoclonal antibodies which recognize the necantigen of PIC are used.
The first method, however, had the defects of a low sensitivity and lack of quantitativeness. The second method had the defects that the PIC cannot be specifically measured. The third method had the defects that, while the sensitivity is good, it is difficult to stably obtain anti-serum; and the immunoreaction is a two-step process,and so the procedure is complicated to require a long time for the measurement. In the fourth method, the defects of the third method were remedied by using a monoclonal antibody against the .alpha..sub.2 -plasmin inhibitor and carrying out the immunoreaction in a single step. However, the fourth method did not solve the defects inherent to the enzyme immunoreaction, that is, the complicated procedure and the long time required for the measurement. Further, the fourth method had the defects that it required the step of diluting the specimen 1200-fold so as to enable the single-step immunoreaction. The fifth method did not exhibit different specificity and measuring sensitivity in comparison with those of the second method wherein a polyclonal antibody is used, and did not solve the problem of the inability of specifically measuring PIC.
The present inventors engaged in research to develop a method for simply and accurately measuring PIC with good reproducibility, and as a result discovered three types of monoclonal antibodies; a first monoclonal antibody (PIC-1) exhibiting reactivity with both PIC and a plasminogen, a second monoclonal antibody (PIC-2) exhibiting reactivity with both PIC and an .alpha..sub.2 -plasmin inhibitor, and a third monoclonal antibody (PIC-3) exhibiting specific reactiv
REFERENCES:
patent: 4216291 (1980-08-01), Collen
patent: 4618589 (1986-10-01), Jefferis et al.
patent: 4629694 (1986-12-01), Harpel
patent: 4820635 (1989-04-01), Sanders et al.
patent: 4840895 (1989-06-01), Self
patent: 4849353 (1989-07-01), Harpel
patent: 5587291 (1996-12-01), Binder
Collen, et al. Biochemica et Biophysica Acta, 525 (1978), 287-290.
Pelzer, et al., Thrombosis and Haemostasis, Abstract 2061.
S. Gonias et al. The Journal of Biological Chemistry, vol. 263, No. 22 5 Aug. 1988, pp. 10903-10906.
P. Harpel et al, Journal of Clinical Investigation, vol 68, Jul. 1981 pp. 46-55.
M. Kawakami et al, Arthritis and Rheumatism, vol. 32, No. 11, Nov. 1989, pp. 1427-1432.
H. Plow et al, Journal of Laboratory Clinical Medicine, Feb. 1979, pp. 199-209.
Lerch et al., "Localization of Individual Lysine-Binding Regions in Human Plasminogen and Investigations on Their Complex-Forming Properties", Eur. J. Biochem., vol. 107, pp. 7-13, (1980).
Hochschwender et al., "Immunochemical Characterization of the Kringle 4 Fragment of Human Plasminogen", The Journal of Biological Chemistry, , vol. 256, No. 21, (1981), pp. 11166-11171.
Pelzer et al., "Determination of .alpha..sub.2 -antiplasmin-plasmin Complex in Human Plasma with an Enzyme-linked Immunosorbent Assay", Fibrinolysis, vol. 7, (1993), pp. 69-74.
Holvoet et al., "A Monoclonal Antibody Specific for Lys-plasminogen", The Journal of Biological Chemistry, vol. 262, No. 22, (1985), pp. 12106-12111.
Hosoda et al., "Homogeneous immunoassay for .alpha..sub.2 plasmin inhibitor (.alpha..sub.2 Pl) and .alpha..sub.2 Pl-plasmin complex", Journal of Immunological Methods, vol. 121, (1989), pp. 121-128.
Mimuro et al., "Monoclonal Antibodies to Discrete Regions in .alpha..sub.2 -Plasmin Inhibitor", Blood, vol. 69, No. 2, (1987), pp. 446-453.
Asakura et al., "Preparation and characterization of monoclonal antibodies against the human thrombin-antithrombin III complex", Biochimica et Biophysica Acta, vol. 952, (1988), pp. 37-47.
Ploplis et al., "Monoclonal Antibodies to Discrete Regions of Human Glu.sub.1 -Plasminogen", Biochemistry, vol. 21, (1982), pp. 5891-5897.
Cummings et al., "Imterspecies Cross-Reactivity of Monoclonal Antibodies to Various Epitopes of Human Plasminogen", vol. 230, No. 1, (1984), pp. 306-315.
Miles et al., "Topography of the High-Affinity Lysine Binding Site of Plasminogen As Defined with a Specific Antibody Probe", Biochemixtry, vol. 25, (1986), pp. 6926-6933.
Kohno Isao
Shiiba Mami
Soe Gilbu
Iatron Laboratories Inc.
Wolski Susan
LandOfFree
Anti-human plasmin-.alpha..sub.2 -plasmin inhibitor complex anti does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-human plasmin-.alpha..sub.2 -plasmin inhibitor complex anti, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-human plasmin-.alpha..sub.2 -plasmin inhibitor complex anti will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1213557